Page 357 of 1,034: studies 3,561 to 3,570 of 10,336, newest first. Back to the depression overview
Nature April 2, 2025
Psilocybin, a classic psychedelic, has therapeutic potential for psychiatric disorders. A specific brain circuit and receptor have now been found to be required for psilocybin’s long-term effects on neural plasticity and depression-related behaviour. The psychedelic psilocybin’s beneficial behavioural action depends on the activation of pyramidal-tract neurons in the frontal cortex.
Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses April 1, 2025 Eleanor Yip, Desiree Fleck 1 citation
Depression is predicted to be the leading burden of disease worldwide by 2030 with a prevalence of 10% to 60% in the surgical population. Depressive symptoms in the perioperative population are associated with a myriad of grave complications, including higher morbidity and mortality. This systematic review aims to determine whether a single dose of intravenous ketamine can be used...
Therapeutische Umschau April 1, 2025 Tobias Bracht, Daniela Hubl, Kristina Adorjan et al. 1 citation
Depression is one of the most common mental disorders. The effectiveness of pharmacological and psychotherapeutic treatments is well documented. Remission rates are around 67 % for pharmacological antidepressant initial and secondary treatment of a depressive episode in unipolar disorders. However, patients with a depressive episode who do not respond to at least two successive attempts at...
Journal of Psychosocial Oncology March 26, 2025 Jennifer Bires
Mood disorders and existential distress impact those with cancer or a serious illness at higher rates than the general population. There have been limited pharmacological advances in recent years, and available psychological interventions vary in degree of impact and durability as a treatment modality in this population. A recent renaissance in psychedelic research has suggested that this class...
The Canadian Journal of Psychiatry March 25, 2025 Noah Chisamore, Erica Kaczmarek, Zoe Doyle et al. 1 citation
Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to participants that discontinued antidepressant medications leading up to receiving psilocybin-assisted psychotherapy (PAP). Methods: Participants (n = 27) received at least one 25 mg...
Advanced Science March 20, 2025 Sung‐hyun Kim, Sumin Yang, Jeehye Jung et al. 5 citations
Abstract Mental disorders are a representative type of brain disorder, including anxiety, major depressive depression (MDD), and autism spectrum disorder (ASD), that are caused by multiple etiologies, including genetic heterogeneity, epigenetic dysregulation, and aberrant morphological and biochemical conditions. Psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have...
Annals of General Psychiatry March 17, 2025 Maurizio Pompili, Isabella Berardelli, Denise Erbuto et al.
Globally, major depressive disorder, or MDD, is a leading cause of disability. It negatively impacts social interactions and significantly limits daily functioning, ultimately reducing life satisfaction. The prevalence rate is about twice as high in women as in males. It is believed that the genesis of major depressive disorder is complicated and includes biological, genetic, environmental, and...
Journal of Holistic Nursing March 17, 2025 Hossam Alhawatmeh, Luay Abusaif, Maryam Alharrasi et al. 2 citations
Purpose: This study aimed to evaluate the effect of mHealth-based mindfulness intervention on trait mindfulness, stress, anxiety, and depression among Registered Nurses caring for patients with COVID-19 in Jordan. Method: Using a pretest-posttest parallel controlled design, 102 nurses from the King Abdullah University Hospital were randomly assigned into experimental (n = 51) and control (n =...
European Journal of Pharmacology March 15, 2025 James J Gattuso, Carey Wilson, Shanshan Li et al. 16 citations
Psilocybin is a serotonergic psychedelic with therapeutic potential for several neuropsychiatric disorders, including depression and anxiety disorders. Serotonin transporter (5-HTT) knockout mice (KO) are a well-validated mouse model of anxiety/depression and are relevant to both chronic treatment with serotonin transporter reuptake inhibitors (SSRIs) and polymorphisms in the serotonin...
BMC Nursing March 14, 2025 Lina Klysing, Ingrid Larsson, Katrin Häggström Westberg 2 citations
Patients suffering from treatment-resistant depression may be treated with nasal esketamine. The treatment requires administration in a healthcare facility and monitoring by a nurse. Existing research has mainly focused on the clinical effect of nasal esketamine, while less is known about patients' experiences of treatment. A person-centred framework provides valuable insights into care and...